Significant improvement in disability scores observed in multiple sclerosis patients who received lemtrada (alemtuzumab) compared with rebif in phase iii trial

Genzyme, 04/25/2012

Genzyme, a Sanofi company, reports additional data from the Phase III CARE–MS II trial. Accumulation of disability was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif (high dose subcutaneous interferon beta–1a), as measured by the Expanded Disability Status Scale (EDSS), a standard assessment of physical disability progression. In addition, significant improvement in disability scores was observed in some patients treated with alemtuzumab from baseline and compared to patients treated with Rebif, suggesting a reversal of disability in these patients.

Print Article Summary Cat 2 CME Report